Cosmo H1 FY26 operating loss widens to EUR 6.61 million; revenue falls to EUR 50.24 million

(AWP Alliance News) - Cosmo Pharmaceuticals NV posted H1 2026 revenue of EUR 50.24 million, while operating loss widened to EUR 6.61 million. Loss attributable to owners deepened to EUR 4.75 million, with basic loss per share at EUR 0.28. Recurring revenue rose 18% to EUR 49.58 million, driven by 38% growth in Winlevi to EUR 10.22 million and a 20% increase in Gastro & CDMO to EUR 30.21 million.

Cash, cash equivalents and investments climbed to EUR 205.15 million at June 30, 2026 from EUR 128.34 million at Dec. 31, 2025. CEO Giovanni Di Napoli said the first half showed "the strength of our execution," highlighting ongoing expansion of Winlevi and continued progress in GI Genius as it evolves into a connected procedural intelligence platform.

https://docs.publicnow.com/B005A232A839EBE951D61BA6DCF94EB8B9D8B352

Disclaimer: This news brief was created using generative artificial intelligence. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.